Literature DB >> 19633967

MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis.

Milena Stosic1, Julian Ambrus, Neeta Garg, Bianca Weinstock-Guttman, Murali Ramanathan, Bernadette Kalman, Alireza Minagar, Frederick E Munschauer, Timothy M Galey, Sara Hussein, Rohit Bakshi, Robert Zivadinov.   

Abstract

MRI findings of primary anti-phospholipid antibody syndrome (PAPLS) are difficult to distinguish from those of multiple sclerosis (MS). Only a few previous studies have compared conventional and non-conventional MRI findings in MS and PAPLS patients. In addition, MRI differences between anti-phospholipid antibody (APLA) positive (+) and APLA negative (-) MS patients have not been reported. Therefore, the aim of this study was to investigate the differences in MRI measures among patients with PAPLS, MS and normal control (NC) subjects. We also explored non-conventional MRI measures in APLA+ and APLA- MS patients. Forty-nine (49) consecutive MS patients among whom 39 had relapsing-remitting (RR) and 10 secondary-progressive (SP) disease course, 30 patients with PAPLS and 49 NC were enrolled. Twenty-eight (28) MS patients were APLA+. MRI measures of T1- and T2-lesion volumes (LV) and brain atrophy, including fractions of whole brain (BPF), gray matter (GMF) and white matter (WMF), were evaluated. The magnetization transfer ratio (MTR) of T2- and T1-LVs and different normal-appearing brain tissue (NABT) compartments as well as diffusion-weighted imaging of whole brain mean parenchyma diffusivity (MPD) were obtained. MS patients differed significantly from NC in all MRI measures. PAPLS patients differed from NC in their T2-LV, in MTR measures and in MPD. When MS patients were compared to PAPLS patients, they showed significantly higher T2- and T1-LVs and T2-LV MTR, lower BPF and GMF and higher MPD. APLA+ RR and SPMS (all APLA+) patients showed significantly higher T2-LV, lower GMF, lower normal-appearing gray matter MTR and higher MPD when compared to APLA- patients. The results indicate that brain abnormalities can be detected in PAPLS patients with non-conventional MRI. MRI reveals more profound injury in patients with MS versus PAPLS. APLA mediates heterogeneous cerebral pathology that remains to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19633967     DOI: 10.1007/s00415-009-5264-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

2.  Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?

Authors:  J W IJdo; A M Conti-Kelly; P Greco; M Abedi; M Amos; J M Provenzale; T P Greco
Journal:  Lupus       Date:  1999       Impact factor: 2.911

3.  Anti-phospholipid antibodies and CD5+ B cells in HIV infection.

Authors:  T Grünewald; G R Burmester; W Schüler-Maué; F Hiepe; F Buttgereit
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 4.  Laboratory evaluation of the antiphospholipid syndrome.

Authors:  Stephen M Abo; Vincent A DeBari
Journal:  Ann Clin Lab Sci       Date:  2007       Impact factor: 1.256

5.  Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.

Authors:  D Paran; J Chapman; A D Korczyn; O Elkayam; O Hilkevich; G B Groozman; D Levartovsky; I Litinsky; D Caspi; Y Segev; V E Drory
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

6.  Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.

Authors:  Eleonora Tavazzi; Michael G Dwyer; Bianca Weinstock-Guttman; Jordan Lema; Stefano Bastianello; Roberto Bergamaschi; Vittorio Cosi; Ralph H B Benedict; Frederick E Munschauer; Robert Zivadinov
Journal:  Neuroimage       Date:  2007-04-10       Impact factor: 6.556

7.  A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?

Authors:  D Karussis; R R Leker; A Ashkenazi; O Abramsky
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

8.  Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients.

Authors:  Neeta Garg; Robert Zivadinov; Murali Ramanathan; Irene Vasiliu; Jaclyn Locke; Kelly Watts; Jordan Lema; Jyotsna Rajeswary; Frederick E Munschauer; Julian Ambrus; Bianca Weinstock-Guttman
Journal:  J Neuroimmunol       Date:  2007-05-18       Impact factor: 3.478

Review 9.  Pathogenesis of axonal and neuronal damage in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Neurology       Date:  2007-05-29       Impact factor: 9.910

10.  Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study.

Authors:  Carlos J Bidot; Lawrence L Horstman; Wenche Jy; Joaquin J Jimenez; Carlos Bidot; Yeon S Ahn; J Steven Alexander; Eduardo Gonzalez-Toledo; Roger E Kelley; Alireza Minagar
Journal:  BMC Neurol       Date:  2007-10-18       Impact factor: 2.474

View more
  11 in total

Review 1.  Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature.

Authors:  Sarthak Gupta; Robert Zivadinov; Deepa Ramasamy; Julian L Ambrus
Journal:  Clin Rheumatol       Date:  2013-11-26       Impact factor: 2.980

Review 2.  Antiphospholipid syndrome and the brain in pediatric and adult patients.

Authors:  E Muscal; R L Brey
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

3.  Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms.

Authors:  Fabricio R Pereira; Francesco Macri; Marcel P Jackowski; William J Kostis; Jean-Christophe Gris; Jean-Paul Beregi; Choukri Mekkaoui
Journal:  Eur Radiol       Date:  2015-07-23       Impact factor: 5.315

Review 4.  White matter lesions and vascular cognitive impairment: part 1: typical and unusual causes.

Authors:  M Nichtweiss; S Weidauer; N Treusch; E Hattingen
Journal:  Clin Neuroradiol       Date:  2012-02-11       Impact factor: 3.649

Review 5.  Aspirin and multiple sclerosis.

Authors:  Sheila Tsau; Mitchell R Emerson; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2015-06-29       Impact factor: 8.775

Review 6.  Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature.

Authors:  Mattias Vågberg; Gabriel Granåsen; Anders Svenningsson
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

Review 7.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

Review 8.  Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.

Authors:  Miguel Leal Rato; Matilde Bandeira; Vasco C Romão; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-14       Impact factor: 5.081

9.  Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

Authors:  Andrew J Solomon; William Hills; Zunqiu Chen; James Rosenbaum; Dennis Bourdette; Ruth Whitham
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

Review 10.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.